Search
HCW Biologics Inc
HCWBAdd to Watchlist
4.300USD
-0.280-6.11%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
14.10MMarket Cap
LossP/E TTM
More Details of HCW Biologics Inc Company
HCW Biologics Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases, such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, autoimmune diseases, as well as other conditions. It has developed a Tissue factOr-Based fusion (TOBI) discovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties. Its lead product candidates include HCW9218 and HCW9302. HCW9218 is a clinical-stage bifunctional molecule that is designed to impact senescence by reducing senescent cells. The Company is prepared to progress HCW9218 in Phase II clinical trials for non-oncology indications.HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes. Its other product candidates include HCW9201, HCW9206, HCW11-006, and others.
HCW Biologics Inc Info
Ticker SymbolHCWB
Company nameHCW Biologics Inc
IPO dateJul 20, 2021
CEOWong (Hing C)
Number of employees36
Security typeOrdinary Share
Fiscal year-endJul 20
Address2929 N Commerce Pkwy
CityMIRAMAR
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code33025
Phone19548422024
Websitehttps://hcwbiologics.com/
Ticker SymbolHCWB
IPO dateJul 20, 2021
CEOWong (Hing C)
Company Executives of HCW Biologics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Hing C. Wong, Ph.D.
Dr. Hing C. Wong, Ph.D.
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
102.63K
--
Mr. Scott T. Garrett
Mr. Scott T. Garrett
Independent Chairman of the Board
Independent Chairman of the Board
33.91K
+87.46%
Ms. Rebecca Byam
Ms. Rebecca Byam
Chief Financial Officer
Chief Financial Officer
9.54K
--
Mr. Lee Flowers
Mr. Lee Flowers
Senior Vice President - Business Development
Senior Vice President - Business Development
953.00
+16.79%
Dr. Peter Rhode, Ph.D.
Dr. Peter Rhode, Ph.D.
Chief Scientific Officer, Vice President - Clinical Operations
Chief Scientific Officer, Vice President - Clinical Operations
323.00
--
Ms. Lisa M. Giles
Ms. Lisa M. Giles
Independent Director
Independent Director
149.00
--
Mr. Rick S. Greene
Mr. Rick S. Greene
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Hing C. Wong, Ph.D.
Dr. Hing C. Wong, Ph.D.
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
102.63K
--
Mr. Scott T. Garrett
Mr. Scott T. Garrett
Independent Chairman of the Board
Independent Chairman of the Board
33.91K
+87.46%
Ms. Rebecca Byam
Ms. Rebecca Byam
Chief Financial Officer
Chief Financial Officer
9.54K
--
Mr. Lee Flowers
Mr. Lee Flowers
Senior Vice President - Business Development
Senior Vice President - Business Development
953.00
+16.79%
Dr. Peter Rhode, Ph.D.
Dr. Peter Rhode, Ph.D.
Chief Scientific Officer, Vice President - Clinical Operations
Chief Scientific Officer, Vice President - Clinical Operations
323.00
--
Ms. Lisa M. Giles
Ms. Lisa M. Giles
Independent Director
Independent Director
149.00
--
FAQs
Who are the top five shareholders of HCW Biologics Inc?
The top five shareholders of HCW Biologics Inc are: Dr. Hing C. Wong, Ph.D.
How many institutions hold shares of HCW Biologics Inc (HCWB)?
As of 2026Q1, 39 institutions hold shares of HCW Biologics Inc, with a combined market value of approximately 465.64K, accounting for 6.91% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 303620.00.